|

Multiple Sclerosis Clinical Trials in Washington, DC

33 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 4<1 mi
Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisN/A<1 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 3<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
An Open-label Study of AZD0120 in Adults With Multiple SclerosisPhase 1<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 3<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 1<1 mi
TSC Biosample Repository and Natural History Database—6 mi
Study of Skin Tumors in Tuberous Sclerosis—6 mi
Genes and Environment in Multiple Sclerosis—6 mi
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Phase 1/26 mi
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis PlaquesPhase 26 mi
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring—6 mi
Pathological Basis of MRI Signal Changes in Multiple Sclerosis—6 mi
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System—6 mi
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)—6 mi
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyPhase 16 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/26 mi
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)—6 mi
Study of the Disease Process of Lymphangioleiomyomatosis—6 mi
Role of Genetic Factors in the Development of Lung Disease—6 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 214 mi
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisPhase 435 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Phase 235 mi
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisN/A35 mi
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral SclerosisPhase 135 mi
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisPhase 135 mi
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot StudyN/A35 mi
Solriamfetol for the Treatment of Multiple Sclerosis FatiguePhase 235 mi
Study of COYA 302 for the Treatment of ALSPhase 235 mi
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisPhase 235 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.